Indivior Pharmaceuticals, Inc. INDV R2KR3KPHARMA
Company Overview
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Why Investors Should Care
Return on capital employed stands at 91.3%.
Revenue has grown at a 11.2% CAGR over the past five years.
Trades at a P/E of 12.7, below the sector median of 25.6.
Maintains a net profit margin of 26.7%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.24B (+4.3% YoY); net profit $210.00M.
- Trailing 12 Months Year-on-year growth — revenue +13.6%, earnings +600.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 11.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 11.20% |
| 1 Year: | 13.60% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 600.00% |
Stock Price Performance
| 1 Year: | +53.81% |
| 6 Months: | +6.54% |
| 3 Months: | -12.82% |
| 1 Month: | -1.62% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- Death Cross1d ago
- RSI (14)50.82 · Neutral
P/E of 12.66 is below the sector median of 25.61 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Healthy ROCE of 91.3%.
- Excellent profit margin of 26.7%.
- Compounding revenue at 11.2% over 5 years.
- Generates positive free cash flow.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INDV Indivior Pharmaceuticals, Inc. R2KR3KPHARMA | 35.33 | 12.66 | $4.17B | 0.00% | 91.29% | - | 11.20% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 284.00M | 299.00M | 307.00M | - | 266.00M | 302.00M | 314.00M | 358.00M | 317.00M | 343.00M |
| Cost of Revenue | - | - | - | - | 44.00M | 52.00M | 83.00M | 67.00M | 40.00M | - |
| Gross Profit | 246.00M | 220.00M | 241.00M | - | 222.00M | 250.00M | 231.00M | 291.00M | 277.00M | 294.00M |
| Operating Expenses | - | - | - | - | 155.00M | 179.00M | 187.00M | 208.00M | 140.00M | - |
| Operating Income | 75.00M | -118.00M | 35.00M | - | 67.00M | 71.00M | 44.00M | 83.00M | 137.00M | 160.00M |
| EBITDA | - | - | - | - | 76.00M | 82.00M | 54.00M | 92.00M | 126.00M | - |
| Interest Expense | - | - | - | - | 12.00M | 15.00M | 12.00M | 6.00M | 7.00M | - |
| Pretax Income | - | - | - | - | 59.00M | 62.00M | 37.00M | 81.00M | 115.00M | - |
| Tax Provision | - | - | - | - | 11.00M | 44.00M | -5.00M | -21.00M | 26.00M | - |
| Net Income | 61.00M | -97.00M | 22.00M | - | 47.00M | 18.00M | 42.00M | 102.00M | 89.00M | 122.00M |
| Diluted EPS | 0.45 | -0.72 | 0.16 | - | 0.38 | 0.14 | 0.33 | 0.79 | 0.69 | 0.98 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 901.00M | 1.09B | 1.19B | 1.24B |
| Gross Profit | 749.00M | 919.00M | 957.00M | 994.00M |
| Operating Income | -81.00M | -152.00M | 38.00M | 262.00M |
| Net Income | -44.00M | -126.00M | 7.00M | 210.00M |
| Diluted EPS | -0.32 | -0.92 | 0.05 | 1.64 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 1.77B | 1.76B | 1.32B | 1.20B |
| Current Assets | - | 1.26B | 1.27B | 827.00M | 652.00M |
| Cash & Equivalents | - | 774.00M | 316.00M | 319.00M | 195.00M |
| Inventory | - | 114.00M | 135.00M | 178.00M | 155.00M |
| Receivables | - | 220.00M | 254.00M | 254.00M | 253.00M |
| Total Liabilities | - | 1.72B | 1.95B | 1.65B | 1.30B |
| Current Liabilities | - | 1.02B | 1.29B | 924.00M | 914.00M |
| Long Term Debt | - | 237.00M | 237.00M | 315.00M | 290.00M |
| Total Debt | - | 277.00M | 283.00M | 375.00M | 351.00M |
| Total Equity | - | 51.00M | -192.00M | -337.00M | -99.00M |
| Shares Outstanding | - | 136.48M | 136.53M | 124.90M | 125.02M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -4.00M | -300.00M | 36.00M | -27.00M |
| Investing Cash Flow | -222.00M | -95.00M | 69.00M | -66.00M |
| Financing Cash Flow | -101.00M | -64.00M | -102.00M | -30.00M |
| Capital Expenditure | -5.00M | -8.00M | -29.00M | -66.00M |
| Free Cash Flow | -9.00M | -308.00M | 7.00M | -93.00M |
| Share Buybacks | 90.00M | 33.00M | 173.00M | 11.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 83.1% | 84.1% | 80.6% | 80.2% |
| Operating Margin % | -9.0% | -13.9% | 3.2% | 21.1% |
| Net Margin % | -4.9% | -11.5% | 0.6% | 16.9% |
| ROE % | -86.3% | 65.6% | -2.1% | -212.1% |
| ROCE % | -10.8% | -32.3% | 9.7% | 91.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.85% | 18.71M | $670.36M |
| 2 | Vanguard Portfolio Management LLC | 6.42% | 7.57M | $271.32M |
| 3 | Oaktree Capital Management LP | 5.19% | 6.13M | $219.54M |
| 4 | Vanguard Capital Management LLC | 4.66% | 5.50M | $196.90M |
| 5 | State Street Corporation | 4.23% | 4.99M | $178.87M |
| 6 | Fuller & Thaler Asset Management Inc. | 3.91% | 4.62M | $165.38M |
| 7 | Two Seas Capital Lp | 3.11% | 3.67M | $131.53M |
| 8 | Morgan Stanley | 2.88% | 3.40M | $121.67M |
| 9 | Franklin Resources, Inc. | 2.81% | 3.32M | $118.83M |
| 10 | Geode Capital Management, LLC | 2.68% | 3.16M | $113.22M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INDV
Indivior Pharmaceuticals, Inc. (INDV) Stock Price, News, Quote & History - Yahoo! Finance Canada
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE5xT294NTRCajQzT2NiVTVMUU84TUZoalpZTDg5OWktb1lhY0FHVkJwbFExNmhrNkZsdlg2N3Yyc05uWmdaNnE3S2Y0YnVPeXNDZWc?oc=5" target="_blank">Indivior Pharmaceuticals, Inc. (INDV) Stock Price, News,…
INDV: Indivior Plc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiSkFVX3lxTE1sdk52YldwY19kX2d2RWs4aklNNUMyeXpvamZVeVAzNnJDMjNKTWVpcloycS1qTExwUGQtSlltRFk5c0JqTkJUZ2hn?oc=5" target="_blank">INDV: Indivior Plc Latest Stock Price, Analysis, News and Trading I…
Indivior Pharmaceuticals Inc (INDV) Stock Up 4.4% but GF Value Says Overvalued -- GF Score: 83/100 - GuruFocus
<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxNUTRvWlZhMUFFd09CU0xUSFF6NmhTUE5EbGV4aFV3S3Uyb18yQmxrWGhrbVcybHI4cDAzR0VxS3drZGs3Q290ei10cHdId0w0Y0E2MDQxcVhITTNqRjRoMkU4Y1RZUWx6TkQxQW9YUVByRjBOM01ELUVHczNhb1Y3akxzSElhUWs5QnQ3Z0…
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend - Indivior
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxORzNDSGZQXzhQbHdFdWFOQlp5RU9XdFJtWmxSU3hPOC16a2tBTkIyemhSNldiRDk5RHNWYzhRLUdCVHNjS1Y4RDR2d2t2NFRvNWIzUTN2S1dYdE15MXl6aktYTXlIY2FqVTliWENHMmtQdktWamlrWnFTLUxKOUJaVElTQ1puUktQbnZyNV…
Third-quarter results are due at 7 a.m. Oct. 29 from Indivior. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxNMG1qT2xwVUwwWFNMeGtrV2toRVlvbWpRQWdFZ1g3RnROeEtoOWZnanlEMC10S19iZ2lURlFLR1loMExXaEhmS0ZxZmpwVHZHaWRscXN6R3RsZ1IxYVIybm01SXY2WllDRjVlNGUzS3pkVHUyQlk1TG1JVTdJZzBGVjJzSVBzWUlkLXRtdj…
Why Did Indivior Pharmaceuticals (INDV) Stock Slide And What Is Behind It? - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxPaTc3dE5oLXBweFRqS3A5dmh5TmJVbDZEaXNoLUM4RG1UX2NsWk0tWFVSOXQxT2d1QzNWMmlvSGo3YlNkdkU3NnMwaVIxT1gyOHFGQ1JrWmxZTkZETVh1YTFZdGo1S01OWnpmOGxWMjR6SlRmVVBHMHNZblRiSFJPS2dnaUpCQnFkRmdMVH…
INDV — Frequently Asked Questions
What is the current share price of Indivior Pharmaceuticals, Inc. (INDV)?
As of 2026-10-22 16:30 PDT, Indivior Pharmaceuticals, Inc. (INDV) trades at $35.33 on NasdaqGS. Its 52-week range is $22.51 to $41.83.
What is the market capitalisation of INDV?
Indivior Pharmaceuticals, Inc. (INDV) has a market capitalisation of $4.17B on NasdaqGS.
What is the P/E ratio of INDV?
INDV trades at a trailing price-to-earnings (P/E) ratio of 12.66. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is -19.78.
Is INDV a good stock to buy?
This page provides a data-driven analysis of Indivior Pharmaceuticals, Inc. (INDV), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.